Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab

Escobar, Gabriela Fortes; Granel‐Brocard, F.; Schmutz, J.‐L.; Cervantes, P.; Mahmoud, Sinan Ben; Bursztejn, Anne‐Claire

doi:10.1111/dth.13951

Cited by 4 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this context, a reasonable step was to develop the new anti-PD1 mAb (IgG4) cemiplimab-rwlc which was approved for the systematic treatment of CSCC in 2018 [ 29 ]. More recent studies have suggested the benefits of cemiplimab treatment in recurrent or metastatic cervical cancer [ 30 ], and advanced or metastatic NSCLC [ 31 ].…”

Section: Anti-pd-1 Antibodiesmentioning

confidence: 99%

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Kovács

Győrffy

2022

J Transl Med

View full text Add to dashboard Cite

The availability of immune-checkpoint inhibitors (ICI) in the last decade has resulted in a paradigm shift in certain areas of oncology. Patients can be treated either by a monotherapy of anti-CTLA-4 (tremelimumab or ipilimumab), anti-PD-1 (nivolumab or pembrolizumab), or anti-PD-L1 (avelumab or atezolizumab or durvalumab) or as combination therapy of anti-CTLA-4 and anti-PD-1. To maximize the clinical treatment benefit of cancer immunotherapy, the prediction of the actual immune response by the identification and application of clinically useful biomarkers will be required. Whole transcriptomic datasets of patients with ICI treatment could provide the basis for large-scale discovery and ranking of such potential biomarker candidates. In this review, we summarize currently available transcriptomic data from different biological sources (whole blood, fresh-frozen tissue, FFPE) obtained by different methods (microarray, RNA-Seq, RT-qPCR). We directly include only results from clinical trials and other investigations where an ICI treatment was administered. The available datasets are grouped based on the administered treatment and we also summarize the most important results in the individual cohorts. We discuss the limitations and shortcomings of the available datasets. Finally, a subset of animal studies is reviewed to provide an overview of potential in vivo ICI investigations. Our review can provide a swift reference for researchers aiming to find the most suitable study for their investigation, thus saving a significant amount of time.

show abstract

Section: Anti-pd-1 Antibodiesmentioning

confidence: 99%

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Kovács

Győrffy

2022

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Escobar et al berichteten über einen Patienten mit fortgeschrittenem cSCC und einem metastasierten NSCLC, der Cemiplimab 3 mg/kg alle 2 Wochen erhielt und außerdem eine Strahlentherapie der Kopfhaut und der Halsregion zur Kontrolle der lokalen Blutung [86]. Der Patient erreichte eine PR und die einzige verbliebene Läsion wurde später exzidiert.…”

Section: Icb Bei Cscc: Wie Ist Die Derzeitige Evidenzlage?unclassified

Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?

et al. 2021

View full text Add to dashboard Cite

Das kutane Plattenepithelkarzinom (cSCC) ist der zweithäufigste Hautkrebs und entsteht vor allem in chronisch sonnengeschädigter Haut. Nachgewiesene Hauptrisikofaktoren sind Immunsuppression, genetische Störungen wie Xeroderma pigmentosum (XP), Exposition gegenüber bestimmten Medikamenten und Umweltnoxen. Therapie der Wahl bei cSCC ist die chirurgische Entfernung, die im Frühstadium meist kurativ erfolgt. Einige wenige Patienten entwickeln jedoch lokal fortgeschrittene Tumoren oder Fernmetastasen, die nach wie vor schwierig zu behandeln sind. Die auf CTLA-4, PD-L1 und PD-1 ausgerichtete Immun-Checkpoint-Blockade (ICB) hat die onkologische Therapie und insbesondere die Behandlung von Hautkrebserkrankungen als Tumoren mit hoher Mutationslast sehr stark verändert. In der vorliegenden Übersichtsarbeit liegt der Fokus auf den Unterschieden zwischen dem kutanen Plattenepithelkarzinom und dem kutanen Melanom (CM) sowie den damit verbundenen Implikationen für die Therapie. Darüber hinaus werden die aktuelle Evidenzlage zur ICB für die Behandlung des fortgeschrittenem cSCC zusammengefasst und die Chancen und Risiken dieser therapeutischen Option für diese Krebsentität erörtert. Ferner richten wir das Augenmerk auf spezielle interessierende Subgruppen von Patienten wie etwa Organtransplantatempfänger, Patienten mit malignen hämatologischen Erkrankungen, XP und Feldkanzerisierung.

show abstract

“…Escobar et al described the case of a patient with both advanced cSCC and metastatic NSCLC who received cemiplimab 3 mg/kg Q2W and radiotherapy of the scalp and cervical region to control local bleeding [86]. The patient responded partially and the only remaining lesion was later excised.…”

Section: Cemiplimabmentioning

confidence: 99%

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Wessely

Steeb

Leiter

et al. 2020

IJMS

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer that predominantly arises in chronically sun-damaged skin. Immunosuppression, genetic disorders such as xeroderma pigmentosum (XP), exposure to certain drugs and environmental noxae have been identified as major risk factors. Surgical removal of cSCC is the therapy of choice and mostly curative in early stages. However, a minority of patients develop locally advanced tumors or distant metastases that are still challenging to treat. Immune checkpoint blockade (ICB) targeting CTLA-4, PD-L1 and PD-1 has tremendously changed the field of oncological therapy and especially the treatment of skin cancers as tumors with a high mutational burden. In this review, we focus on the differences between cSCC and cutaneous melanoma (CM) and their implications on therapy, summarize the current evidence on ICB for the treatment of advanced cSCC and discuss the chances and pitfalls of this therapy option for this cancer entity. Furthermore, we focus on special subgroups of interest such as organ transplant recipients, patients with hematologic malignancies, XP and field cancerization.

show abstract

Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab

Cited by 4 publications

References 6 publications

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Contact Info

Product

Resources

About